Immune checkpoint inhibitor-associated interstitial nephritis: let’s move forward addressing the unknowns

Clicks: 17
ID: 329630
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #148 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
ABSTRACT Immune checkpoint inhibitors (ICI) are now well recognized as a cause of acute interstitial nephritis (ICI-AIN), and their increasingly widespread use explains the growing incidence of reported cases. This clinicopathological entity is characterized by acute kidney injury with a tubulointerstitial pattern occurring in a patient exposed to an ICI, and histological confirmation is required to establish the diagnosis. Histopathological examination typically reveals a lymphocytic infiltrate, supporting the use of corticosteroid therapy for approximately 12 weeks, which enables recovery of kidney function in more than 80% of cases. Although current recommendations are relatively well established, daily management remains challenging for nephrologists in a number of patients. In practice, nephrologists are not dealing with a single form of nephritis, but rather with several distinct entities, whose identification is progressively emerging through the literature, particularly with the description of different histopathological subtypes. We therefore sought to highlight specific patient populations for whom diagnostic, therapeutic, and prognostic management remains difficult despite the available literature.
Reference Key
openalex_W7214218131 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Julie Bellière, Ben Sprangers
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag333
URL
https://doi.org/10.1093/ckj/sfag333
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.